Identification of Two Novel Immune Subtypes Characterized by Distinct Prognosis and Tumor Microenvironment in Osteosarcoma

Figure 8

Chemotherapeutic sensitivity between high and low TIIC subtypes. Estimated median inhibition concentration (IC50) of (a) cisplatin, (b) methotrexate, and (c) doxorubicin.

(a)

(b)

(c)